1-Year Results Favor Monthly Ibandronate Dosing Over Daily

Article

First-year data from the 2-year MOBILE study of monthly administration of ibandronate for postmenopausal osteoporosis have been released. All women achieved significant response, but women taking the agent once a month had a greater increase in bone mineral density (BMD) than similar women taking the drug on a daily schedule.

First-year data from the 2-year MOBILE study of monthly administration of ibandronate for postmenopausal osteoporosis have been released. All women achieved significant response, but women taking the agent once a month had a greater increase in bone mineral density (BMD) than similar women taking the drug on a daily schedule.

John Sunyecz, from Laurel Highlands Ob/Gyn in Hopwood, PA, revealed the planned responders analysis of the MOBILE study in a poster yesterday. The double-blind multinational study randomized 1,609 women with postmenopausal osteoporosis to three study arms: Ibandronate 150 mg monthly, 100 mg monthly, and 2.5 mg daily. All of the women took the drug with plain water immediately upon rising in the morning and at least 1 hour before food or other medications. Participants also received daily calcium and vitamin D supplements.

After the first year of the study, nearly all of the women in each arm showed increases in lumbar spine BMD. But women on the monthly regimens were significantly more likely to achieve or exceed the study endpoints, greater than 6% increase in lumbar spine BMD or greater than 3% increase in total hip BMD.

Among women taking 150 mg, 35.3% gained at least 6% in lumbar spine BMD, compared with 32.2% of those taking 100 m, and 24.2% of those on the daily dosing schedule. For total hip BMD, 48.4% of women in the 150 mg and 43.4% of women in the 100 mg group showed an increase of more than 3%. Among women in the daily dosing group, 34.9% met the same goal.

Sunyecz J. Better clinical response for once-monthly compared with daily oral ibandronate. Obstet Gynecol. 2005;105(4 suppl):108S.

Recent Videos
Trina Mansour, MD
Negative pressure wound therapy reduces c-section infections and costs | Image Credit: doctors.valleyhealth.com.
Amy Valent DO, MCR, highlights new tech for prenatal diabetes management | Image Credit: linkedin.com.
Lisa Bayer, MD, MPH
Megan Wasson, DO, FACOG
Megan Cohen, MD, MPH, outlines 2024 CDC contraception guidelines | Image Credit: linkedin.com.
Wasson and Colak
Johanna Finkle, MD, weight loss specialist, OB/GYN, The University of Kansas Health System.
Navigating hormone therapy in high-risk menopause cases | Image Credit: © dhaj7-cepo.com.
Tia Welsh, MD, highlights breakthroughs in cervical cancer screening | Image Credit: doctors.valleyhealth.com.
Related Content
© 2025 MJH Life Sciences

All rights reserved.